Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 12/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26611833 | 0.86 | ALDH1A1 (0.55) | ALOX5PTGS2HTR2APPARAPPARG | |
| SCHEMBL27001993 | 0.85 | HTR2A (0.56) | ALOX5PTGS2HTR2APPARAPPARG | |
| SCHEMBL27002063 | 0.85 | HTR2A (0.56) | ALOX5PTGS2HTR2APPARAPPARG | |
| SCHEMBL12831233 | 0.84 | ALDH1A1 (0.50) | KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL11297175 | 0.81 | TYR (0.51) | ALOX5PTGS2PPARAPPARGKDM4E | |
| SCHEMBL5319676 | 0.81 | ALDH1A1 (0.47) | ALOX5PTGS2HTR2AKDM4EALDH1A1 | |
| SCHEMBL1527130 | 0.78 | TYR (0.51) | ALOX5PTGS2PPARAPPARGKDM4E | |
| SCHEMBL8154554 | 0.78 | TYR (0.51) | ALOX5PTGS2PPARAPPARGKDM4E | |
| SCHEMBL11158133 | 0.78 | ERN1 (0.47) | KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL27904720 | 0.78 | TYR (0.49) | ALOX5KDM4EALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117642379-A | Phenylalkylamines and methods of making and using the same | 吉尔伽美什制药公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4305019-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | Gilgamesh Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192781-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | PNMT, HTR6, HTR2C | ALOX5 574/4885PTGS2 1481/4885HTR2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.